为了早期癌症诊断中检测肺癌的肿瘤标志物癌胚抗原（CEA），本研究旨在开发一种基于金属-有机框架（MOF）-氧化石墨烯纳米复合物修饰的无标记电化学免疫传感器，该传感器的主体为抗CEA抗体/Ag-MOF/GO/GCE。通过超声辐射法在GCE表面上制备了Ag-MOF/GO纳米复合物，然后将抗CEA抗体固定在表面上。通过FE-SEM和XRD分析修饰电极的晶体结构和形貌，发现正确组合的GO纳米片和Ag-MOF纳米颗粒具有较大的表面积以捕获抗体。利用CV和DPV方法进行的电化学测试表明，抗CEA/Ag-MOF/GO/GCE提高了免疫传感器的敏感性、稳定性和选择性。结果显示，在0.005 ng/mL的检测限下，还原峰电流的变化与范围在10-3至5000 ng/mL的CEA浓度的对数呈负相关。本文探讨了建议的CEA免疫传感器在人血清样品中的适用性，并通过ELISA和DPV方法进行的标准加入技术的分析研究结果显示，两种方法的结果存在显著一致性。另外，回收率范围为99.00%至99.25%，所有样品检测的相对标准偏差（RSDs）均低于5.01%，表明所提出的CEA免疫传感器的测量结果准确可靠，说明本研究制备的CEA免疫传感器可用于临床应用和人体液体。版权所有 © 2023. 由Elsevier Inc.发表。

In order to detect carcinoembryonic antigen (CEA) as a tumor marker in lung cancer for early cancer diagnosis, this study aimed to develop a label-free electrochemical immunosensor based on the immobilization of an Anti-CEA antibody on a metal-organic framework (MOF)-graphene oxide nanocomposite modified glassy carbon electrode (Anti-CEA/Ag-MOF/GO/GCE). Ag-MOF/GO nanocomposite was prepared on the GCE surface using the ultrasonic irradiation method, and Anti-CEA antibody was subsequently immobilized on the surface. Analysis of the crystal structure and morphology of the modified electrode using FE-SEM and XRD revealed that the correct combination of GO nanosheets and Ag-MOF nanoparticles produced a high surface area to trap the antibodies. Electrochemical tests utilizing the CV and DPV methods revealed that the immunosensor's sensitivity, stability, and selectivity were improved by Anti-CEA/Ag-MOF/GO/GCE. Results showed that, with a detection limit of 0.005 ng/mL, the change in the reduction peak current was inversely correlated with the logarithm concentration of CEA in the range of 10-3 to 5000 ng/mL. The suggested CEA immunosensor's applicability in a human serum sample was investigated, and findings of analytical studies via standard addition technique for both ELISA and DPV assays revealed that significant agreement existed between the outcomes of the two assays. Additionally, the recoveries ranged from 99.00% to 99.25%, and all relative standard deviations (RSDs) for the sample detections were below 5.01%, indicating satisfactory accuracy in results measured with the proposed CEA immunosensor, indicating that the prepared CEA immunosensor in this study can be used in clinical applications and human fluids.Copyright © 2023. Published by Elsevier Inc.